Overview

A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia

Status:
Completed

Trial end date:
2016-04-15

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized study in subjects with heterozygous familial hypercholesterolemia receiving highly effective statins to assess the safety, efficacy and tolerability of Bococizumab (PF-04950615; RN316) to lower LDL-C.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Bococizumab